Abstract
Aim:
The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of 125I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Patients & methods:
The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015.
Results & conclusion:
Compared with the TACE treatment alone, the combination therapy of 125I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCC patients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCC patients with PVTT.
Keywords:
125I seed; TACE; hepatocellular carcinoma; portal vein tumor thrombosis.
Publication types
-
Comparative Study
-
Evaluation Study
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Brachytherapy / adverse effects
-
Brachytherapy / methods*
-
Carcinoma, Hepatocellular / complications
-
Carcinoma, Hepatocellular / mortality
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / therapy*
-
Chemoembolization, Therapeutic / adverse effects
-
Chemoembolization, Therapeutic / methods
-
Combined Modality Therapy / adverse effects
-
Combined Modality Therapy / methods
-
Endosonography
-
Female
-
Humans
-
Iodine Radioisotopes / administration & dosage*
-
Liver / blood supply
-
Liver / diagnostic imaging
-
Liver / pathology
-
Liver Neoplasms / complications
-
Liver Neoplasms / pathology
-
Liver Neoplasms / therapy*
-
Male
-
Middle Aged
-
Portal Vein / diagnostic imaging
-
Retrospective Studies
-
Survival Rate
-
Treatment Outcome
-
Venous Thrombosis / etiology
-
Venous Thrombosis / mortality
-
Venous Thrombosis / therapy*
Substances
-
Iodine Radioisotopes
-
Iodine-125